Featured Studies

Myelodysplastic syndromes (MDS) are disorders caused by abnormal blood cell production, potentially leading to low cell counts and increased susceptibility to clotting and infections. Past research suggests that inflammation may trigger these abnormalities, and this study seeks to further understand and improve treatment strategies for MDS by investigating the role of inflammation in bone marrow cell development.

Doctors at the National Institutes of Health (NIH) are conducting a research study to determine the viability and safety of early initiation of oral therapy with cyclosporine and eltrombopag in patients with severe aplastic anemia (SAA).

Pharmacologic therapy with Bruton's tyrosine kinase (BTK) inhibitors is associated with an increased risk of heart problems like atrial fibrillation, bleeding, and high blood pressure (hypertension) which can lead to sudden death. There is currently no standard for cardiac screening or monitoring patients on BTK inhibitors. Researchers at the National Heart, Lung, and Blood Institute (NHLBI) are investigating the relationship between the development of heart problems in patients on BTKi as it relates to other variables.

Researchers at the National Human Genome Research Institute (NHGRI) are seeking healthy children between 2-17 years old to participate in a research study to better understand the immune system of patients with mitochondrial disease in comparison to their healthy peers.

Do you... Find yourself constantly checking things? Spend lots of time ordering your belongings? Have unusual rituals or habits that seem unnecessary? Do you blurt out comments at inappropriate times, interrupt conversations or speak out of turn or feel you are overly impulsive? The National Human Genome Research Institute (NHGRI) is conducting an outpatient research study on the links between compulsivity, impulsivity and the developing brain in children and young adults.

Researchers from the National Cancer Institute at the NIH Clinical Center are currently looking for patients who have HER2-expressing endometrial cancer. The purpose of the study is to test two investigational study drugs, a vaccine that targets HER2 (AdHER2DC) and a drug that is expected to improve immune cell function (N-803). These study drugs will be used with pembrolizumab and lenvatinib which are FDA approved to treat endometrial cancer.